中国实用医刊
中國實用醫刊
중국실용의간
Chinese Journal of Practical Medicine
2015年
21期
80-81,82
,共3页
付勇先%范瑞%郑香玉%高峰%孙征%孙冉
付勇先%範瑞%鄭香玉%高峰%孫徵%孫冉
부용선%범서%정향옥%고봉%손정%손염
乳腺癌%免疫组化方法%CerbB2%ER%PR%Ki67
乳腺癌%免疫組化方法%CerbB2%ER%PR%Ki67
유선암%면역조화방법%CerbB2%ER%PR%Ki67
Breast cancer%Immunohistochemistry%CerbB2%ER%PR%Ki67
目的:分析CerbB2、ER、PR、Ki67在乳腺癌中的表达及其意义。方法抽取南阳市第一人民医院经临床病理证实的乳腺癌患者90例作为乳腺癌组,取同期乳腺良性病者87例作为对照组,两组患者入院后均行免疫组化检查,并记录CerbB2、ER、PR、Ki67表达。结果乳腺癌组CerbB2、ER、PR、Ki67基因的阳性表达率分别为60.0%、48.89%、55.56%、72.22%,均显著高于对照组,差异具有统计学意义( P<0.05)。腋窝淋巴转移患者的CerbB2、PR、Ki67阳性率为50.98%、33.33%、90.20%,与对照组比较,差异均有统计学意义;浸润性导管癌患者CerbB2、Ki67阳性率分别为21.05%、47.37%,显著低于浸润性小叶癌、髓样癌, ER、PR阳性率分别为89.47%、78.95%,显著高于浸润性小叶癌、髓样癌,差异均有统计学意义( P<0.05)。结论 CerbB2、ER、PR、Ki67表达对乳腺癌诊断、治疗具有指导意义,可作为预后评估指标。
目的:分析CerbB2、ER、PR、Ki67在乳腺癌中的錶達及其意義。方法抽取南暘市第一人民醫院經臨床病理證實的乳腺癌患者90例作為乳腺癌組,取同期乳腺良性病者87例作為對照組,兩組患者入院後均行免疫組化檢查,併記錄CerbB2、ER、PR、Ki67錶達。結果乳腺癌組CerbB2、ER、PR、Ki67基因的暘性錶達率分彆為60.0%、48.89%、55.56%、72.22%,均顯著高于對照組,差異具有統計學意義( P<0.05)。腋窩淋巴轉移患者的CerbB2、PR、Ki67暘性率為50.98%、33.33%、90.20%,與對照組比較,差異均有統計學意義;浸潤性導管癌患者CerbB2、Ki67暘性率分彆為21.05%、47.37%,顯著低于浸潤性小葉癌、髓樣癌, ER、PR暘性率分彆為89.47%、78.95%,顯著高于浸潤性小葉癌、髓樣癌,差異均有統計學意義( P<0.05)。結論 CerbB2、ER、PR、Ki67錶達對乳腺癌診斷、治療具有指導意義,可作為預後評估指標。
목적:분석CerbB2、ER、PR、Ki67재유선암중적표체급기의의。방법추취남양시제일인민의원경림상병리증실적유선암환자90례작위유선암조,취동기유선량성병자87례작위대조조,량조환자입원후균행면역조화검사,병기록CerbB2、ER、PR、Ki67표체。결과유선암조CerbB2、ER、PR、Ki67기인적양성표체솔분별위60.0%、48.89%、55.56%、72.22%,균현저고우대조조,차이구유통계학의의( P<0.05)。액와림파전이환자적CerbB2、PR、Ki67양성솔위50.98%、33.33%、90.20%,여대조조비교,차이균유통계학의의;침윤성도관암환자CerbB2、Ki67양성솔분별위21.05%、47.37%,현저저우침윤성소협암、수양암, ER、PR양성솔분별위89.47%、78.95%,현저고우침윤성소협암、수양암,차이균유통계학의의( P<0.05)。결론 CerbB2、ER、PR、Ki67표체대유선암진단、치료구유지도의의,가작위예후평고지표。
Objective To analyze the expression and significance of CerbB2, ER, PR, Ki67 in breast cancer. Methods Selected 90 cases proved by pathology as breast cancer as cancer group, and 87 cases over the same period of benign breast disease as control group.Patients of the two groups underwent immunohistochemical examination after admis-sion, and recorded the expression of CerbB2, ER, PR, Ki67 gene.Results Positive expression of CerbB2, ER, PR, Ki67 gene in breast cancer group was 60%, 48.89%, 55.56%, 72.22%, which were higher than those in the control group, there were significant differences(P<0.05).CerbB2, PR, Ki67 positive rate of axillary lymphatic metastasis pa-tients was 50.98%, 33.33%, 90.20%, which were significantly different between the control group and cancer group;CerbB2, Ki67 positive rates of invasive ductal cancer patients were 21.05%and 47.37%, which were significantly lower than those of invasive lobular carcinoma, medullary carcinoma;the positive rates of PR and ER were 89.47% and 78.95%, which were significantly higher than those of invasive lobular carcinoma, medullary carcinoma, and the differ-ences were significant( P<0.05) .Conclusions Expression of CerbB2, ER, PR, Ki67 has guiding significance in the di-agnosis and treatment of breast cancer, it can be used as the index of evaluating prognosis.